Promising fda-approved drugs with efflux pump inhibitory activities against clinical isolates of staphylococcus aureus

HIGHLIGHTS

• who: Safaa Abdel-Aal Mohamed Abdel-Karim et al. from the Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt have published the research: Promising FDA-approved drugs with efflux pump inhibitory activities against clinical isolates of Staphylococcus aureus, in the Journal: PLOS ONE of 23/03/2022
• what: In the study , the FDA-approved drugs as diclofenac sodium, domperidone, GTN and metformin were investigated for their EPI activities against S. aureus at their 1/8 MICs.
• how: This study aimed to investigate the efflux mechanism in S. aureus and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.